Litcius/Paper detail

Development and comparison of three 89Zr-labeled anti-CLDN18.2 antibodies to noninvasively evaluate CLDN18.2 expression in gastric cancer: a preclinical study

Guilan Hu, Wenjia Zhu, Yu Liu, Yuan Wang, Zheng Zhang, Shikun Zhu, Wenwen Duan, Peipei Zhou, Chao Fu, Fang Li, Li Huo

2022European Journal of Nuclear Medicine and Molecular Imaging39 citationsDOI

Topics & Concepts

BiodistributionIn vivoEx vivoChemistryCancerAntibodyMolecular biologyIn vitroMedicineImmunologyBiochemistryBiologyBiotechnologyInternal medicineCell Adhesion Molecules ResearchGlycosylation and Glycoproteins ResearchGalectins and Cancer Biology
Development and comparison of three 89Zr-labeled anti-CLDN18.2 antibodies to noninvasively evaluate CLDN18.2 expression in gastric cancer: a preclinical study | Litcius